Stock listing

LS Exchange:A0LCUL Catalyst Pharmaceuticals, Inc. Aktie

German listing (LS Exchange) of Catalyst Pharmaceuticals, Inc. · home listing NASDAQ:CPRX

Follow Catalyst Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Catalyst Pharmaceuticals, Inc. logo
Ticker
LS Exchange:A0LCUL
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All Catalyst Pharmaceuticals, Inc. news

Catalyst Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
13 in the last 12 months · 180 in all · newest Jun 30, 2026 · oldest 2019
Calls
18 calls with a replay · 18 with a transcript · latest Feb 26, 2026
Decks
6 decks · latest Feb 26, 2026

Where Catalyst Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CPRX · Home listingNASDAQUnited StatesUSD
gettex:CN2gettexGermanyEUR
LS Exchange:A0LCUL · This pageLS ExchangeGermanyEUR
BOATS:CPRXBOATSUnited StatesUSD
Tradegate:CN2TradegateGermanyEUR
Frankfurt:CN2FrankfurtGermanyEUR
Lang & Schwarz:A0LCULLang & SchwarzGermanyEUR
BX Swiss:CN2BX SwissSwitzerlandCHF
Stuttgart:CN2StuttgartGermanyEUR
Dusseldorf:CN2DusseldorfGermanyEUR
Hamburg:CN2HamburgGermanyEUR
Munich:CN2MunichGermanyEUR

Valuation

Statements: 4 quarters to Mar 31, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
82.3%
Operating margin
44.8%
Net margin
37.1%
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
31.67 USD · Analysts' mean
EPS, year to Dec 2026
3.17 · 1 analyst
Revenue, year to Dec 2026
636.2M · 2 analysts

Team and board

Officers

OfficerRole
Mary ColemanInvestor Relations
Chantal DresnerVP of Marketing
Roberto ScrivoChief External Affairs Communication & Sustainability Officer
William T. AndrewsChief Medical Officer

Board

DirectorRole
Daniel CurranDirector
Internal CommunicationDirector

Events

Calls

CallWhenStatus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2025 Earnings CallThu, May 08, 2025 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2024 Earnings CallThu, Feb 27, 2025 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2024 Earnings CallThu, Nov 07, 2024 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2024 Earnings CallThu, May 09, 2024 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2023 Earnings CallThu, Feb 29, 2024 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:30 AM ETReplay
All 18 calls
CallWhenStatus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2023 Earnings CallThu, Aug 10, 2023 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2023 Earnings CallThu, May 11, 2023 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2022 Earnings CallThu, Mar 16, 2023 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2022 Earnings CallThu, Nov 10, 2022 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2022 Earnings CallWed, Aug 10, 2022 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2022 Earnings CallWed, May 11, 2022 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2021 Earnings CallThu, Mar 17, 2022 · 8:30 AM ETReplay
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:30 AM ETReplay

Results days

QuarterResults
Q1 2026May 11, 2026 · After close
Q4 2025Mar 18, 2026
Q3 2025Nov 5, 2025 · After close
Q2 2025Aug 6, 2025 · After close
Q1 2025May 6, 2025 · Before open
Q4 2024Feb 26, 2025 · After close
Q3 2024Nov 6, 2024 · After close
Q2 2024Aug 7, 2024 · After close
Q1 2024May 8, 2024 · After close
Q4 2023Feb 28, 2024 · After close
All 20 quarters
QuarterResults
Q3 2023Nov 8, 2023 · After close
Q2 2023Aug 9, 2023 · After close
Q1 2023May 10, 2023 · After close
Q4 2022Mar 15, 2023 · After close
Q3 2022Nov 9, 2022 · After close
Q2 2022Aug 9, 2022 · After close
Q1 2022May 10, 2022 · After close
Q4 2021Mar 16, 2022 · After close
Q3 2021Nov 9, 2021 · After close
Q2 2021Aug 9, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Q4 2025 Earnings PresentationEarnings21 slidesFeb 26, 2026
Investor Presentation (January 2026)Investor deck21 slidesJan 12, 2026
J.P. Morgan Healthcare Conference 2025Conference20 slidesJan 13, 2025
Investor Presentation (January 2024)Investor deck26 slidesJan 8, 2024
Investor Presentation (September 2023)Investor deck25 slidesSep 26, 2023
Catalyst Pharmaceutical Partners — BIO CEO Investor Conference 2013Conference27 slidesFeb 14, 2013

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue589.0M491.7M398.2M214.2M140.8M119.1M102.3M500.0K00
Cost of revenue87.3M68.8M52.0M34.4M21.9M17.0M14.8M19.9M45.7K43.4K
Gross profit501.7M422.9M346.2M179.8M118.9M102.0M87.5M500.0K-45.7K-43.4K
Research and development12.7M12.6M93.2M19.8M16.9M16.5M18.8M19.9M11.4M11.4M
Selling, general and administrative71.5M167.7M47.0M28.7M23.5M20.7M36.9M15.9M7.30M7.91M
Operating income257.8M195.1M86.8M101.8M52.4M41.3M31.8M-35.3M-18.7M-19.3M
Depreciation and amortization37.9M37.8M32.9M1.24M192.0K885.3K297.7K38.0K45.7K43.4K
EBITDA295.7M232.9M119.7M103.1M52.6M42.2M32.1M-35.3M-18.6M-19.2M
Interest expense4.12M474.0K1.47M1.88M1.29M454.2K321.6K
Income before tax283.5M216.3M94.5M104.7M52.7M41.9M33.4M-34.0M-18.4M-18.1M
Income tax69.2M52.4M23.1M21.6M13.2M-33.1M1.53M2.58M141.2K-929.5K
Net income214.3M163.9M71.4M83.1M39.5M75.0M31.9M-34.0M-18.4M-18.1M
Earnings per share, basic1.681.310.630.750.370.710.30-0.33-0.21-0.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents709.2M517.6M137.6M298.4M171.4M130.2M89.5M16.6M57.5M13.9M
Short-term investments019.8M10.0M5.01M36.9M26.5M26.5M
Receivables128.3M65.5M53.5M10.8M6.72M5.99M10.5M
Inventory37.2M19.5M15.6M6.80M7.87M4.65M1.96M56.0K00
Current assets894.0M623.6M219.3M320.8M210.1M159.2M111.4M55.2M85.2M41.5M
Property, plant and equipment847.0K3.98M129.8K210.5K245.4K191.4K244.2K
Goodwill00
Total assets1.11B851.4M470.1M375.6M237.8M192.4M112.4M60.4M85.4M41.7M
Accounts payable11.2M16.6M14.8M3.98M2.77M4.26M4.12M2.34M1.95M933.2K
Current liabilities147.2M120.7M76.1M57.6M27.1M22.8M24.1M9.51M4.27M2.09M
Long-term debt00
Total debt2.79M3.19M3.56M3.89M4.20M29.0K948.0K
Total liabilities152.5M123.8M82.2M75.2M31.0M22.8M24.7M9.67M4.42M2.40M
Shareholders' equity954.3M727.6M387.9M300.4M206.8M169.6M87.6M50.8M81.0M39.3M
Shares outstanding127.3M124.9M113.8M111.4M107.8M106.2M106.0M102.6M85.8M82.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations208.7M239.8M143.6M116.0M60.4M45.0M34.6M-25.7M-13.7M-18.0M
Capital spending-58.0K-556.0K-81.7M-29.0K-1.02M-11.4K-19.4K-92.0K-92.0K-96.1K
Free cash flow208.6M239.3M61.9M116.0M59.4M45.0M34.6M-25.8M-13.7M-18.1M
Cash from investing-58.0K-556.0K-293.5M9.21M-11.0M-5.01M37.2M-15.5M-3.96K3.55M
Cash from financing-17.0M140.7M-10.9M1.69M-8.14M701.9K1.12M293.1K57.4M69.0K
Dividends paid00
Share buybacks-25.3M-296.0K-982.0K-6.91M-12.1M-56.0K1.12M-4.45K57.4M-11.3K
Change in cash191.6M379.9M-160.8M127.0M41.2M40.7M73.0M-40.9M43.6M-14.3M

Open Financials

Cap table

Built by 6ix from Catalyst Pharmaceuticals, Inc.’s releases

Common shares
122,417,458
Fully diluted
122,417,458

Fully diluted

LineShares
Common shares122,417,458

Share count over time

CountShares
Nov 22, 2026122,417,458

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Glenmede Trust Co NA651K0.53%US$12.8M+150KNov 16, 2026
IFP Advisors, Inc1,533<0.01%US$48,175−1,430Oct 16, 2026

Funds

HolderSharesOf the companyValueChangeAs of
iShares Core S&P Small-Cap ETF6.93M5.7%US$218M−5,144Jun 30, 2026
Avantis U.S. Small Cap Value ETF4.17M3.4%US$130M+996KMay 31, 2026
Vanguard Total Stock Market Index Fund3.7M3.0%US$116M−13,788Jun 30, 2026
iShares Russell 2000 ETF3.02M2.5%US$95M+186KJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.99M2.4%US$93.8M+717KJun 30, 2026
Nexpoint Merger Arbitrage Fund1.43M1.2%US$44.9MNewJun 30, 2026
Vanguard Extended Market Index Fund1.32M1.1%US$41.4M+30,242Jun 30, 2026
iShares Russell 2000 Growth ETF1.09M0.89%US$34.2M+144KJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF1.05M0.86%US$33M+6,403Jun 30, 2026
iShares S&P Small-Cap 600 Growth ETF1.03M0.84%US$32.5M+36,371Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Tax-Managed Small-Cap Fund746K0.61%US$23.5MNo changeJun 30, 2026
The Arbitrage Fund724K0.59%US$22.6MNewMay 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF649K0.53%US$20.4M+39,868Jun 30, 2026
Fidelity Extended Market Index Fund598K0.49%US$18.7M−5,560May 31, 2026
Vanguard Russell 2000 Index Fund595K0.49%US$18.6M+21,126May 31, 2026
Schwab U.S. Small-Cap ETF556K0.45%US$17.4M−6,037May 31, 2026
Vanguard S&P Small-Cap 600 Index Fund400K0.33%US$12.5M+3,777May 31, 2026
First Trust Merger Arbitrage Fund356K0.29%US$11.2MNewJun 30, 2026
Vanguard Health Care Index Fund350K0.29%US$10.9M+917May 31, 2026
Voya Small Cap Growth Fund324K0.26%US$10.1M+3,633May 31, 2026
Fidelity Enhanced Small Cap Core ETF297K0.24%US$9.33M+71,489Jun 30, 2026
Avantis U.S. Small Cap Equity ETF244K0.20%US$7.63M+11,853May 31, 2026
Oberweis Micro-Cap Fund228K0.19%US$7.17M−462KJun 30, 2026
Boston Partners Small Cap Value Fund II223K0.18%US$6.98M+32,583May 31, 2026
Master Small Cap Index Series216K0.18%US$6.8M+24,587Jun 30, 2026
Fidelity Total Market Index Fund216K0.18%US$6.75MNo changeMay 31, 2026
JNL Small Cap Index Fund180K0.15%US$5.66M+1,010Jun 30, 2026
Fidelity Series Total Market Index Fund176K0.14%US$5.48M+2,348May 31, 2026
William Blair Small Cap Value Fund174K0.14%US$5.48M−5,269Jun 30, 2026
Columbia Small Cap Index Fund172K0.14%US$5.39M−11,435May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF147K0.12%US$4.61M+3,536Jun 30, 2026
Vanguard S&P Small-Cap 600 Growth Index Fund137K0.11%US$4.29M+8,446May 31, 2026
Avantis U.S. Small Cap Value Fund128K0.10%US$4MNo changeMay 31, 2026
EQ/2000 Managed Volatility Portfolio128K0.10%US$4.02M+6,382Jun 30, 2026
Principal U.S. Small-Cap ETF119K0.10%US$3.75M+8,496Jun 30, 2026
JPMorgan Small & Mid Cap Enhanced Equity ETF115K0.09%US$3.61M+4,570Jun 30, 2026
BlackRock Advantage Small Cap Core Fund112K0.09%US$3.51M−226KMay 29, 2026
Fidelity Small Cap Growth Index Fund110K0.09%US$3.47M+22,316Jun 30, 2026
AST Small-Cap Equity Portfolio109K0.09%US$3.44M−5,632Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund109K0.09%US$3.39M+2,606May 31, 2026
Convergence Long/Short Equity ETF101K0.08%US$3.14M+27,192May 31, 2026
PSF Small-Cap Stock Index Portfolio99,3690.08%US$3.12MNo changeJun 30, 2026
Virtus NFJ Small-Cap Value Fund97,4160.08%US$3.06MNewJun 30, 2026
Invesco S&P SmallCap Quality ETF96,2330.08%US$3.01M+3,347May 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF92,2610.08%US$2.88M−3,232May 31, 2026
BlackRock Advantage Small Cap Growth Fund86,6610.07%US$2.72M+27,061Jun 30, 2026
Avantis U.S. Equity ETF85,9320.07%US$2.68M+1,070May 31, 2026
VictoryShares Small Cap Free Cash Flow ETF83,1960.07%US$2.61M−52,894Jun 30, 2026
LVIP State Street Small-Cap Index Fund83,1000.07%US$2.61M+5,000Jun 30, 2026
Invesco S&P SmallCap Health Care ETF80,9300.07%US$2.53M−15,246May 31, 2026

This page holds 50 of 225 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
BlackRock, Inc.13.90%16.9MMar 31, 2025
State Street Corp5.20%6.41MSep 30, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
William T. Andrews
Other companies: Flexion Therapeutics Inc (Chief Medical Officer · Jul 1, 2021 – Nov 19, 2021 · Past); Akcea Therapeutics Inc (Chief Medical Officer · Jul 9, 2020 – Oct 12, 2020 · Past); Acer Therapeutics Inc (Chief Medical Officer · Oct 2, 2017 – Mar 2, 2020 · Past); Aegerion Pharmaceuticals Inc (See Remarks · Mar 29, 2015 – Aug 4, 2015 · Past)
Chief Medical Officer · Since at least Jun 2, 2025
David S Tierney
Other companies: Timber Pharmaceuticals Inc (Pres and CEO · Sep 11, 2018 – Jun 12, 2019 · Past); Zevra Therapeutics, Inc. (Director · Apr 15, 2015 – Mar 9, 2023 · Past); Bioject Medical Technologies Inc (Director · Jun 14, 2007 – Apr 30, 2014 · Past)
Director · Since at least Oct 27, 2015
Daniel J. Curran
Other companies: ALX Oncology Holdings Inc. (Director · Since at least Aug 12, 2025); Xilio Therapeutics, Inc. (Board Member · Since at least Oct 21, 2021)
Director · Since at least Aug 1, 2025
Michael Wayne Kalb
Other companies: CinCor Pharma Inc (EVP & Chief Financial Officer · Nov 4, 2022 – Feb 24, 2023 · Past); Amarin Corporation plc (SVP and CFO · Jun 30, 2016 – Jul 29, 2022 · Past)
Chief Financial Officer · Since at least Jan 1, 2024
Philip H Coelho
Other companies: Mediware Information Systems Inc (Director · Jan 3, 2012 – Nov 9, 2012 · Past); Ampio Pharmaceuticals, Inc. (Director · Nov 22, 2011 – Dec 30, 2021 · Past)
Director · Aug 25, 2015 – May 4, 2023 · Past
Richard J Daly
Other companies: Aquestive Therapeutics, Inc. (Director · Since at least Nov 10, 2026); Opiant Pharmaceuticals Inc (Director · Jun 15, 2021 – Mar 2, 2023 · Past)
President and CEO, Director · Since at least Dec 22, 2020
Tamar Thompson
Other companies: Avidity Biosciences, Inc (Director · Since at least Jan 11, 2021)
Director · Since at least May 25, 2023
Alicia GrandeVP, Treasurer and CFO · Aug 25, 2015 – Dec 27, 2023 · Past
Brian ElsberndChief Legal Officer · Since at least Dec 27, 2018
Chantal DresnerVP of Marketing · Since at least Nov 4, 2025
All 24 people
PersonSeat
Charles B O'KeeffeDirector · Aug 25, 2015 – Feb 14, 2025 · Past
Daniel BrennanChief Commercial Officer · Dec 2, 2019 – Dec 2, 2019 · Past
Donald A DenkhausDirector · Since at least Dec 30, 2015
Gary IngenitoChief Med. & Reg. Officer · Jun 30, 2015 – May 13, 2025 · Past
Gregg RussoChief HR Officer · Since at least Feb 13, 2025
Internal CommunicationDirector · Since at least May 7, 2026
Jeffrey Del CarmenChief Commercial Officer · Since at least Jun 23, 2020
Mary ColemanInvestor Relations · Since at least Jan 23, 2025
Molly HarperDirector · Since at least Jun 29, 2021
Patrick J McEnanyDirector · Since at least Aug 18, 2022
Paul J MerriganChief Commercial Officer · Sep 8, 2015 – Dec 30, 2015 · Past
Preethi SundaramChief Strategy Officer · Since at least Jul 6, 2021
Roberto ScrivoChief External Affairs Communication & Sustainability Officer · Since at least May 7, 2026
Steve MillerChief Op. & Scientific Officer · Since at least Aug 25, 2015

Open People

Log in to ask 6ix AI your own questions about Catalyst Pharmaceuticals, Inc.